
Best Practices in Gynecologic Oncology 2026
Advancing care in gynecologic oncology
GLOBAL LEARNING OBJECTIVES
At the end of this accredited Section 3 CPD activity, participants will be able to:
-
assess their knowledge and practice in the management of gynecologic cancers in light of current evidence, recent guidelines, and discussions of complex clinical cases;
-
identify gaps between their current practice and best practices in gynecologic oncology, particularly with respect to the integration of biomarkers, the selection of multimodal treatments, innovative surgical approaches, and patients’ quality of life;
-
determine concrete and applicable practice improvement strategies to optimize personalized, safe, interdisciplinary, and equitable care for patients with gynecologic cancers.

The event program may be subject to minor changes at the discretion of the scientific committee.
SATURDAY, JUNE 13, 2026
7:30-8:00
Networking Breakfast
8:00-9:15
Advanced and Metastatic Endometrial Cancer
Learning Objectives
At the end of this session, participants will be able to:
-
integrate the FIGO 2024 classification, including molecular classification, into the assessment and management of advanced and metastatic endometrial cancer;
-
select personalized treatment strategies based on the patient’s clinical, pathological, and molecular profile;
-
recognize approaches that may reduce treatment-related toxicity and preserve quality of life in women with advanced and metastatic endometrial cancer.
Dr. Marie-Claude Renaud and Dr. Alexandra Sebastianelli, CHU de Québec
9:15-10:30
Vulvar Cancer
Learning Objectives
At the end of this session, participants will be able to:
-
analyze the indications for and limitations of multimodal therapeutic strategies in the treatment of vulvar cancer;
-
recognize the current and potential role of biomarkers in individualizing care;
-
determine approaches aimed at reducing treatment-related morbidity and improving patients’ quality of life.
Dr. Céline Lechartier, gynecologic oncologist, and Dr. Hugo Villeneuve, radiation oncologist, CIUSSS du Saguenay–Lac-Saint-Jean
10:30-11:00
Networking Break
11:00-12:15
Recurrent Ovarian Cancer: Platinum-Sensitive and Platinum-Resistant Disease
Learning Objectives
At the end of this session, participants will be able to:
-
compare treatment strategies according to whether recurrence is platinum-sensitive or platinum-resistant;
-
recognize biomarkers that are useful for treatment selection and for estimating therapeutic response;
-
identify strategies to overcome treatment resistance while taking patients’ quality of life into account.
Dr. Élizabeth Tremblay, gynecologic oncologist, CHUM
12:15-13:15
Lunch
13:15-14:30
Locally Advanced and Recurrent Cervical Cancer
Learning Objectives
At the end of this session, participants will be able to:
-
analyze the best multimodal treatment options for patients with locally advanced or recurrent cervical cancer;
-
integrate biomarkers and relevant clinical characteristics into treatment personalization;
-
recognize interventions that may reduce treatment-related morbidity and improve patients’ quality of life.
Dr. Paul Bessette, gynecologic oncologist, CHU Sherbrooke
14:30-15:45
Innovative Surgical Approaches and Ovarian Cancer
Learning Objectives
At the end of this session, participants will be able to:
-
assess the indications, benefits, and limitations of cardiophrenic lymph node resection in ovarian cancer cytoreduction;
-
analyze the technical principles and safety considerations associated with complex diaphragmatic surgery;
-
recognize the contribution of advanced technologies to the planning and performance of extensive cytoreduction.
(To be confirmed)
15:45-16:15
Networking Break
16:15-17:15
Tumour Board
Learning Objectives
At the end of this session, participants will be able to:
-
analyze, through complex clinical cases, optimal integrative strategies applicable in gynecologic oncology in 2026;
-
assess the contribution of an interdisciplinary approach to decision-making and care optimization;
-
identify organizational, clinical, or systemic limitations that influence the delivery of care to patients with gynecologic cancer and determine opportunities for improvement.
Dr. Léonie Dallaire-Nantel, CIUSSS du Saguenay–Lac-Saint-Jean
17:15
Closing Remarks
Scientific Committee
Become Our Partner
RGOQ is the partner of choice for healthcare organizations, hospitals, patient advocacy groups, pharmaceutical companies, and medical device manufacturers that share our vision and commitment. By partnering with us, you join a network of professionals and organizations dedicated to improving patient outcomes and advancing the field of gynecologic oncology.



.png)

